Sorafenib increases 18-FDG colic uptake demonstration in patients with differentiated thyroid cancer 英文参考文献.docVIP

Sorafenib increases 18-FDG colic uptake demonstration in patients with differentiated thyroid cancer 英文参考文献.doc

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
Sorafenib increases 18-FDG colic uptake demonstration in patients with differentiated thyroid cancer 英文参考文献

Ciappuccinietal.EJNMMIResearch2012,2:18 /content/2/1/18 SHORT COMMUNICATION OpenAccess Sorafenibincreases18-FDGcolicuptake: demonstrationinpatientswithdifferentiated thyroidcancer RenaudCiappuccini1*,GéraldineTrzepla2,NatachaHeutte3,EmmanuelSevin4, MariePierreGalais4andStéphaneBardet1 Abstract Background:Toassess18-fluorodeoxyglucose(FDG)boweluptakeinpatientswithdifferentiatedthyroidcancer (DTC)treatedwithsorafenib. Findings:Visual(5-pointscale)andhighmaximumstandarduptakevalue(SUVmax)semi-quantitativeanalyses wereconductedin63positronemissiontomography(PET)studiesperformedinpatientsonsorafenib(group1, n=20),inacontrolgroup(group2,n=28)andinpatientsonsunitiniborvandetanib(group3,n =15). Moderateorhighanddiffuseboweluptake(grade4or5)wasobservedin90%ofthePETscansofgroup1versus noneingroup2.Only20%ofPETscansingroup3werescoredgrade4.SUVmaxvaluesweresignificantlyhigher forallcolicsegmentsingroup1thaningroup2(P0.0001)or3(P0.0004).Thisuptakepatternappearedrapidly (onemonth)anddisappearedaftersorafenibwithdrawal. Conclusions:FDGuptakeisincreasedinthecolonofDTCpatientstreatedbysorafenib. Keywords:Sorafenib,FDGPET,Thyroidcancer,Colicuptake Findings Background patients treated by other TKI such as sunitinib and vandetanib. Sorafenibisanewtargetedtherapywithanangiogenesis inhibitingactivity,belongingtothetyrosinekinaseinhi- bitors (TKI) family [1]. This multikinase inhibitor has beenevaluatedinvariouscancerswithpromisingresults [2-4], including in medullary [5] and in differentiated thyroid cancer (DTC) [6,7]. In the first patients with DTC treated by sorafenib in our unit, we often noticed anintenseanddiffuse18-Fluorodeoxyglucose(FDG)up- takeintheabdomen.Theaimofthepresentretrospect- ive work was to assess the proportion of patients with such an uptake, to determine the uptake pattern in the small intestine and in the colon, to evaluate the scinti- graphic outcome pattern after sorafenib withdrawal when possible and to compare this uptake with that of Methods Patients Betwe

您可能关注的文档

文档评论(0)

1234554321 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档